AbbVie has wrapped up its late-stage studies of a promising interferon-free hepatitis C cocktail, setting the stage for near-term FDA application and a showdown with rival Gilead Sciences.

…read more

Source: AbbVie’s hep C hopeful aces PhIII and sets off an arms race with Gilead